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ABSTRACT
Background: Patients with diabetes are at increased
risk of acute coronary syndromes (ACS) and their
mortality and morbidity outcomes are significantly
worse following ACS events, independent of other
comorbidities. This systematic review sought to
establish the optimum management strategy with
focus on P2Y12 blockade in patients with diabetes with
ACS.
Methods: MEDLINE (1946 to present) and EMBASE
(1974 to present) databases, abstracts from major
cardiology conferences and previously published
systematic reviews were searched to June 2014.
Relevant randomised control trials with
clinical outcomes for P2Y12 inhibitors in adult
patients with diabetes with ACS were scrutinised
independently by 2 authors with applicable data was
extracted for primary composite end point of
cardiovascular death, myocardial infarction (MI)
and stroke; enabling calculation of relative risks with
95% CI with subsequent direct and indirect
comparison.
Results: Four studies studied clopidogrel in patients
with diabetes, with two (3122 patients) having primary
outcome data showing superiority of clopidogrel
against placebo with RR0.84 (95% CI 0.72–0.99).
Irrespective of management strategy, the newer agents
prasugrel (2 studies) and ticagrelor (1 study) had a
lower primary event rate compared with clopidogrel;
RR 0.80 (95% CI 0.66 to 0.97) and RR 0.89 (95% CI
0.77 to 1.02), respectively. When ticagrelor was
indirectly compared with prasugrel, there was a trend
to an improved primary outcome with prasugrel (RR
1.11 (95% CI 0.94 to 1.31)) particularly in those
managed with percutaneous coronary intervention
(PCI) (RR 1.23 (95% CI 0.95 to 1.59)). Prasugrel
demonstrated a statistical superiority with prevention of
further MI with RR 1.48 (95% CI 1.11 to 1.97). This
was not at the expense of increased major
thrombolysis in MI (TIMI) bleeding rates RR 0.94
(95% CI 0.59 to 1.51).
Conclusions: This meta-analysis shows the addition
of a P2Y12 inhibitor is superior to placebo, with a
trend favouring the use of prasugrel in patients
with diabetes with ACS, particularly those undergoing
PCI.
BACKGROUND
Acute coronary syndromes (ACS) are a spec-
trum of cardiovascular conditions charac-
terised by the presence of an unstable
atherosclerotic plaque with overlying throm-
bus.1 Globally, the prevalence of diabetes
mellitus (DM) is increasing,2 3 and given
that this population is well described to
have increased platelet reactivity,4–6 it is
unsurprising that in large landmark
KEY QUESTIONS
What is already known about this subject?
▸ In acute coronary syndrome (ACS), clopidogrel
in addition to aspirin shows a reduction in car-
diovascular death, myocardial infarction and
stroke. However, in the patient with diabetes,
there has been a suggestion of a muted
response to clopidogrel, cited as multifactorial,
including genetic, metabolic, cellular and clin-
ical. This has increased the interest in more
novel P2Y12 receptor antagonists, such as pra-
sugrel and ticagrelor.
What does this study add?
▸ In patients with diabetes with ACS, the addition
of a P2Y12 receptor inhibitor is superior to
placebo in reducing cardiovascular mortality,
non-fatal myocardial infarction, and non-fatal
stroke without significantly increasing major
bleeding events.
▸ Prasugrel is superior to clopidogrel, with a trend
to superiority against ticagrelor in this cohort,
particularly in those undergoing percutaneous
coronary intervention, without amplified risk of
major bleeding.
How might this impact on clinical practice?
▸ Guidance committees need to consider a more
tailored approach to ACS management.
▸ The findings from this study support further ran-
domised control trials directly comparing prasu-
grel and ticagrelor, particularly in the diabetes
population.
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antiplatelet trials, as many as 15–39% of all patients
presenting with ACS have a background of DM7 8; this
ﬁgure correlates well with registry data percentages
(GRACE registry 26%, Swedeheart registry 24%,
PACIFIC registry 35%).9–11 Furthermore, this popula-
tion is known to have worse mortality and morbidity
outcomes compared to patients without diabetes; inde-
pendent of other comorbidities.12
This increased aggregation of platelets in DM is driven
primarily by hyperglycaemia affecting a multitude of
pathways including increasing p-selectin expression via
activation of protein kinase C, impaired function of
endogenous antiplatelet agents such as nitric oxide and
prostacyclin,13 ampliﬁed platelet adhesion,14 a proin-
ﬂammatory environment2 and increased platelet turn-
over.15 Importantly, upregulation of P2Y12 signalling and
GPIIb/IIIa surface receptors are also implicated.3 14
Therefore, with the focus of pharmacological manage-
ment of ACS being the reduction of thrombus burden
and platelet reactivity,16 17 targeting P2Y12 receptors is of
great importance particularly in this population, who
may stand to receive the most beneﬁt.
Until recently, clopidogrel was the most widely used
P2Y12 receptor inhibitor in addition to aspirin, following
randomised control trial data showing a reduction in
cardiovascular death, myocardial infarction (MI) and
stroke.8 18 19 However, in the patient with diabetes, there
has been a suggestion of a muted response to clopido-
grel, which has been cited as multifactorial, including
genetic, metabolic, cellular and clinical.20 21 This has
increased the interest in more novel P2Y12 receptor
antagonists, such as prasugrel and ticagrelor. Published
data has led to preferential use of these agents in the
general population,7 22 23 and possible better outcomes
with prasugrel in the cohort with diabetes,2 15 but no
speciﬁc data has been systematically reviewed with both
direct and indirect comparison for the management of
the patient with diabetes.
Review question
To establish, through the available literature, the
optimum antiplatelet therapy practice for management
of patients with DM who present with ACS.
The speciﬁc review questions:
1. In combination with aspirin, which is the superior
agent for P2Y12 blockade to improve the primary
outcome of cardiovascular (CV) death, non-fatal MI
and non-fatal stroke (CV accident, CVA)?
2. Is this beneﬁt outweighed by increased risk of major
bleeding (secondary outcome)?
METHODS
This review was reported in accordance with the
PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) guidelines,24 and a protocol
prior to embarking on search was written (see online
supplementary appendix 5).
Search strategy and study selection
MEDLINE and EMBASE databases were systematically
searched up to 18 June 2014 with no date or language
restrictions. The search threads were limited to human,
adult (≥18 years) and randomised controlled trials
evaluating: clopidogrel, cangrelor, ticagrelor, prasugrel,
elinogrel, P2Y12 receptor antagonist, P2Y12 receptor
inhibitor, ADP receptor antagonist or ADP receptor
inhibitor. The results were combined with the Boolean
operator ‘OR’ and linked to Medical Subject Headings.
Following exclusion of duplicates, the retrieved titles
and abstracts were independently screened by two
authors ( JAR and OIB) for relevant studies with focus
on coronary artery disease. The full texts for the remain-
ing studies were obtained.
The authors reviewed these residual articles by elec-
tronically searching the studies for the word stems
‘diab’, ‘mellitus’ or ‘DM’. Studies were excluded if they
did not contain these terms, or only included in baseline
patient characteristics. Each ﬁgure was individually
searched to ensure no data relating to a diabetes
patients subset. Also explored was the documentation of
supplementary data using stem ‘supplement’, ‘append’
and ‘online’. This data was then evaluated for results
relevant to the review. Medically trained peers ﬂuent in
that language translated the foreign language papers
discovered.
Finally, the authors again independently assessed for
the presence of clinical outcome data for ACS (ACS, ST
elevation MI, non-ST elevation MI and unstable angina)
distinct from stable disease. The remaining studies were
analysed to conﬁrm there was clinical outcome data of
P2Y12 receptor inhibition in patient with diabetes pre-
senting with ACS. Any discrepancies in results were
resolved by group consensus.
In parallel with the systematic search process, we
searched for studies in major cardiology conference
abstract databases (American Heart Association (AHA),
American College of Cardiology and European Society
of Cardiology (ESC)). Further we retrieved other
meta-analyses of antiplatelet agents reviewing the studies
included and manually searched the references to
ensure no relevant studies were missed.
Data extraction
The authors scrutinised the resulting studies, and rele-
vant data was extracted, as outlined in the protocol. This
included: title, author(s), country, publication year,
study period, patient population, treatment arms,
outcome deﬁnition, follow-up duration, overall inci-
dence, diabetes patients subgroups, number of patients
and relative risks with 95% CI.
The outcome measures included both primary and
secondary outcome measures. Primary outcome mea-
sures mentioned were: CV mortality, non-fatal MI, non-
fatal CVA, and any other relevant clinical end point.
Secondary outcomes incorporated, but were not limited
to, major bleeding. Methodological quality was assessed
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via the ‘The Cochrane Collaboration’s tool for assessing
risk of bias’ utilising the protocol or design and rationale
papers to aid.25 Any discrepancies were resolved by
group meeting and discussion with a third investigator if
agreement not met (AH).
Data synthesis
The eligible studies were entered into RevMan5 software
package, and the statistical methods were programmed
into RevMan V.5.3 analysis software.
The number in each comparator group and the
number of events were extracted. For the dichotomous
data, the risk ratios (RR) along with 95% CIs were calcu-
lated. In cases of common comparators and outcomes,
the results were pooled using the ﬁxed effects and
random effects models dependent on heterogeneity.
Heterogeneity was explored with the Cochrane Q statis-
tic, which was considered to be signiﬁcant if p<0.10, and
if signiﬁcant a random effect model was used to allow
generalisation of the results. Z tests were used to test for
the overall effect.
Indirect comparison analysis of relative risk was per-
formed to evaluate prasugrel versus ticagrelor, and both
newer P2Y12 inhibitors against control. This was com-
pleted using Bucher’s method.26
RESULTS
Literature search
Articles numbering 1162 were identiﬁed on the search
of MEDLINE and EMBASE following restriction to
human adult randomised control trials. Review of the
title and abstract excluded 896 papers, with elimination
of 184 articles due to failure to mention diabetes
beyond baseline characteristics. Absence of clinical out-
comes or a separate ACS cohort resulted in exclusion of
further 65 articles. Therefore, 17 papers, consisting of
study populations from seven randomised control trials
were included in the analysis.7 8 18 19 22 27–38 The search
overview can be found in online supplementary appen-
dix 2. Study populations, design and outcomes are docu-
mented in online supplementary appendix 4.
Seven papers evaluated clopidogrel as the intervention
of interest in four study populations. Two studies com-
pared clopidogrel with placebo in addition to aspirin
therapy.8 18 32 One reviewed clopidogrel against
aspirin,19 37 and ﬁnally one population examined
double-dose clopidogrel versus standard-dose therapy in
a 2×2 factorial design with aspirin low and high
doses.33 34
Seven papers were written based on data from two
study cohorts comparing prasugrel with clopido-
grel,7 22 28–31 38 and three relevant papers generated
from single study examining ticagrelor versus clopido-
grel.27 35 36 The initial trials were all found to be high
quality and low risk of bias, as demonstrated in online
supplementary appendix 1; using Cochrane risk of bias
tool.25 Each study’s treatment arms were balanced for
characteristics and management strategy (eg, coronary
artery bypass grafting (CABG), PCI or ﬁbrinolysis,
dependent on the study).
Diabetes versus non-diabetes
The importance of assessing the population of patients
with diabetes in the ACS patient group was highlighted
Figure 1 Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death,
non-fatal MI and non-fatal CVA) as a percentage of the population in TRITON-TIMI 38 (prasugrel) and PLATO (ticagrelor)
studies, exploring effects of presence of diabetes and nature of management.27 29 CV, cardiovascular; CVA, CV accident; MI,
myocardial infarction; TIMI, thrombolysis in myocardial infarction.
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by the universal agreement that patients with diabetes
have a worse outcome, notably with the predominant
primary composite end point (CV mortality, non-fatal
MI and non-fatal CVA)8 27 29 and MI.27 37 Management
of patients with diabetes with insulin conferred a worse
primary outcome still29 (ﬁgure 1). Insulin use is likely to
be a surrogate marker for severity of diabetes, as the
population with type 1 diabetes will comprise only a
minority of these patients. Data from PLATO shows that
type 1 diabetes accounted for only 4% of their total
population with diabetes.27
In the studies that statistically assessed for interaction
between patients with and without diabetes, the majority
found that there was no signiﬁcant difference in the
overall results.19 22 27 34 The exception to this was
TRITON-TIMI 38 which found that the diabetes popula-
tion had superior beneﬁt from prasugrel compared to
clopidogrel in the reduction in fatal/non-fatal (MI; HR
0.60 (95% CI 0.48 to 0.76) (patient with diabetes)
versus HR 0.82 (95% CI 0.72 to 0.95) (patients without
diabetes (Pinteraction=0.02)), and composite of all-cause
death, MI, CVA and major bleed unrelated to CABG
(HR 0.74 (95% CI 0.62 to 0.89) versus HR 0.92 (95% CI
0.82 to 1.03 (Pinteraction=0.05)).
7 29
Clopidogrel versus placebo
In 3122 patients from two randomised studies, treatment
with clopidogrel was associated with a signiﬁcant reduc-
tion in CV death, non-fatal MI and non-fatal stroke at
30–360 days (RR 0.84 (95% CI 0.71 to 0.99)). The
larger study looked at patients managed both medically
and with revascularisation (36.4%),32 whereas the
second studied only those undergoing a percutaneous
invasive strategy.8 There was no statistical heterogeneity
(Q=0.68, p=0.41, I2=0%), so ﬁxed effects were calculated
(ﬁgure 2).
High-dose versus low-dose clopidogrel
In light of the favourable results of clopidogrel versus
placebo CURRENT-OASIS 7 looked at 25 086 patients
referred for percutaneous coronary intervention (PCI)
following presentation with ACS. Patients were assigned
either double dose or standard therapy clopidogrel, and
high-dose or low-dose aspirin. In the prespeciﬁed sub-
group of diabetes, there was a non-signiﬁcant beneﬁt of
higher dose clopidogrel in primary composite end point
rate (CV death, non-fatal MI and CVA) with RR 0.85
(95% CI 0.69 to 1.05 (p=0.13)).34
Ticagrelor versus clopidogrel
The PLATO study compared ticagrelor and clopidogrel
as P2Y12 inhibitor in addition to aspirin in ACS patients
managed with and without coronary intervention. The
diabetes patient population was a prespeciﬁed subgroup
that was subsequently analysed showing additional
beneﬁt with ticagrelor reducing composite of CV death,
non-fatal MI and non-fatal CVA (RR 0.89 (95% CI 0.77
to 1.02) p=0.10) over a 12-month follow-up period.27
Interestingly, compared to the whole study population
(RR 0.85 (95% CI 0.78 to 0.92) p=0.0002), the diabetes
patient cohort results were not statistically signiﬁcant.23
Reassuringly, in the patients with diabetes, there was no
increased risk of major bleeding as deﬁned by PLATO,27
with RR 0.95 (95% CI 0.81 to 1.10 (p=0.47)).
Prasugrel versus clopidogrel
The two studies with prasugrel and clopidogrel as com-
parators were TRITON-TIMI 38 and TRILOGY,7 22
which evaluated the ACS population managed with
scheduled PCI and no revascularisation, respectively. A
total population of 6690 with diabetes was monitored for
events predetermined with the composite primary end
point of CV death, non-fatal MI and CVA, for the dur-
ation of follow-up (14.5–30 months). Heterogeneity was
observed (Q=3.15, p=0.08, I2=68%), so the RR was calcu-
lated using the random effects model. The overall effect
was in favour of prasugrel in the diabetes patient popula-
tion RR 0.80 (95% CI 0.66 to 0.97) (ﬁgure 3).
From the TRITON-TIMI 38 data, we can also elicit
beneﬁts of prasugrel over clopidogrel in the population
with diabetes, with reduction in MI (RR 0.62 (95% CI
0.50 to 0.76) p≤0.01) and deﬁnite/probable stent
thrombosis (RR 0.56 (95% CI 0.36 to 0.86) p=0.01)
events. This advantage is consolidated in the knowledge
there is no increase in major bleeding risk associated
(RR 0.95 (95% CI 0.61 to 1.46) p=0.81).29 Interestingly,
Figure 2 Clopidogrel versus
placebo; risk ratio with 95% CIs
for the primary composite end
point of CV death, non-fatal MI
and non-fatal CVA in the diabetes
population comparing clopidogrel
versus placebo in addition to
aspirin. CV, cardiovascular; CVA,
CV accident; MI, myocardial
infarction; PCI, percutaneous
coronary intervention.
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TRITON-TIMI 38’s outcomes appear better in the dia-
betes patient cohort compared to the total enrolled
population whose RR 0.82 (95% CI 0.74 to 0.91
(p≤0.01)).7
Insulin-dependent diabetes patients versus
non-insulin-dependent diabetes patients
Three studies further divided the population with dia-
betes, categorising by insulin use.27 29 37 CAPRIE study
showed that there was variable response to antiplatelet
therapies in the acute setting dependent on the nature
of management of the patient. An absolute risk reduc-
tion of 3.8% with clopidogrel treatment compared to
aspirin therapy in annual event rate for those managed
on insulin against 2.1% overall for the population with
diabetes.37
A subsequent analysis has shown that the beneﬁt of
the newer P2Y12 inhibitor was more pronounced in the
group treated on insulin with a reduction in risk of 36%
with prasugrel and 22% with ticagrelor, compared to
24% and 8%, respectively, in the non-insulin treatment
arm. However, these were not adequately powered and
failed to reach statistical signiﬁcance (Pinteraction=0.2 for
prasugrel and Pinteraction=0.13 for ticagrelor).
27 29
Reassuringly, there was no increased risk of major bleed-
ing risk in any group, independent of antiplatelet or
DM management strategy (ﬁgure 4).
Indirect comparison
Ticagrelor versus prasugrel
In the diabetes patient population, we were able to indir-
ectly compare a number of outcomes that showed no
statistical difference, however, a trend to prasugrel’s
superiority with regard to the composite primary end
point of CV death, non-fatal MI and non-fatal CVA, par-
ticularly in the cohort undergoing PCI.27 29 35 A signiﬁ-
cant 33% risk reduction in MI events favouring
prasugrel was noted. Regarding safety parameters, there
was no difference in deﬁnite/probable stent thrombosis
(RR 1.19 (95% CI 0.58 to 2.45)) or major thrombolysis
in myocardial infarction (TIMI) bleeding events (RR
0.94 (95% CI 0.59 to 1.51)) (ﬁgure 5).
Newer P2Y12 inhibitor versus placebo
No clinical studies have compared the newer P2Y12 inhi-
bitors to placebo for ethical, clopidogrel in addition to
placebo has already been proven to be of signiﬁcant
beneﬁt, and practical reasons, shift to predominant
Figure 4 Prasugrel and
ticagrelor versus clopidogrel; risk
ratio with 95% CIs for the primary
composite end point of
cardiovascular death, non-fatal
myocardial infarction and
non-fatal stroke. Also, major
bleeding in the diabetic
populations managed with and
without insulin; comparing
prasugrel and ticagrelor versus
clopidogrel in addition to aspirin.
Event rate percentage of newer
agent versus clopidogrel. DM,
diabetes mellitus.
Figure 3 Prasugrel versus
clopidogrel; risk ratio with 95%
CIs for the primary composite end
point of cardiovascular death,
non-fatal myocardial infarction
and non-fatal stroke in the
diabetic population comparing
prasugrel versus clopidogrel in
addition to aspirin.
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invasive strategy in ACS treatment as stent implantation
mandates the use of dual antiplatelet therapy. However,
using the indirect comparison method we were able to
conﬁrm the superiority of the newer agents against
placebo. This showed a marked reduction in the com-
posite end point of cardiovascular death, non-fatal MI
and CVA (ﬁgure 6). There was further suggestion of pra-
sugrel’s clinical superiority in this population.
DISCUSSION
This review shows that all evaluated P2Y12 inhibitors are
superior in preventing ischaemic events compared to
placebo in diabetic patients with ACS. The newer agents,
such as ticagrelor and prasugrel, have a more favourable
outcome when directly compared with clopidogrel,
although ticagrelor failed to reach statistical signiﬁcance.
This was without an increased risk of bleeding (see
online supplementary appendix 3).
There may be added value in the cohort managed on
insulin, but these results were not powered to reach stat-
istical importance. When indirectly analysed, there is a
signiﬁcant beneﬁt in reduction of events of MI with pra-
sugrel compared with ticagrelor in the diabetes patient
group; with a trend to superiority relating to primary
clinical outcomes, especially in those undergoing PCI.
Possible mechanisms
The clinical outcomes of patients with diabetes with ACS
on clopidogrel monotherapy are superior to those on
aspirin.37 It is therefore not surprising that when clopi-
dogrel is combined with aspirin the outcomes are
favourable in reduction of ischaemic events, versus
placebo with aspirin. Patients with diabetes are more
likely to be resistant to aspirin,39 and in addition, have
increased P2Y12 receptor signalling.
14 Therefore, this
cohort may have ampliﬁed beneﬁt from the addition of
a P2Y12 receptor antagonist to the thromboxane A2
inhibitor aspirin compared to their non-diabetes
counterparts.
Patients with diabetes have a higher level of platelet
reactivity compared to the non-diabetes population.4 So
the search for more potent inhibitors is especially
important in this group. We have demonstrated from
the analysis, that prasugrel and ticagrelor are superior to
both placebo and clopidogrel. Regarding the newer
agents versus clopidogrel, these ﬁndings are supported
by trials of platelet function testing showing increased
inhibition of aggregation with less variable response.40
This is likely to be multifactorial, but a large contribu-
tory is non-response to clopidogrel. Research shows that
depending on method of assessment, 38–44% of
patients with diabetes are non-responders to clopidogrel
compared to 8–17% of patients without diabetes at
24 h.6 The level of poor response is still apparent at
7 days (24–53%),21 40 and is combined with lower levels
of circulating active clopidogrel metabolite.21 41
Non-response to clopidogrel is a well-documented
phenomenon attributed to a number of plausible factors
such as increased clearance, reduced absorption altered
Figure 5 Ticagrelor versus
prasugrel; risk ratio with 95% CIs
for the primary composite end
point, primary composite end
point in those undergoing PCI,
myocardial infarction, definite/
probable stent thrombosis and
major bleeding (TIMI
classification) in the diabetes
population, indirectly comparing
ticagrelor versus prasugrel in
addition to aspirin. MI, myocardial
infarction; PCI, percutaneous
coronary intervention; TIMI,
thrombolysis in MI.
Figure 6 P2Y12 blockade
versus placebo; risk ratio with
95% CIs for the primary
composite end point of
cardiovascular death, non-fatal
myocardial infarction and
non-fatal stroke in the diabetes
population, comparing P2Y12
blockade versus placebo in
addition to aspirin.
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metabolism to the active clopidogrel metabolite, and
higher platelet turnover.3 Also, potential genetic factors
have been linked possibly related to the abnormalities in
CYP expression in the diabetes patient population.42
However, the predominant mechanism appears to be
the abnormal metabolism of clopidogrel within the dia-
betes patient population rather than dysfunction of the
P2Y12 receptor or its signalling pathway, as ex-vivo add-
ition of active metabolite results in almost complete nor-
malisation of response compared to controls.21 41
In non-responders, increased on-medication platelet
reactivity is signiﬁcantly correlated to major adverse car-
diovascular events (CV death, ACS or stroke), with an
increase in event rate from 13.2% to 37.7% at 2 years in
patients with diabetes whose level of platelet reactivity is
in the upper fourth quartile.43 Concern over non-
responders/subresponders led to exploration of high-
dose clopidogrel (150 mg) in the patient with diabetes.
Although this did signiﬁcantly reduce platelet aggrega-
tion, nonetheless, the majority remained categorised as
a subresponder,44 which may explain the lack of statistic-
ally important beneﬁt to double-dose clopidogrel in clin-
ical outcomes.34
This has solidiﬁed the potential importance of the
newer agents, prasugrel and ticagrelor. In the general
population, they have been shown to be superior to clo-
pidogrel in suppression of aggregation,20 45 46 even in
those where patients are subjected to double-dose clopi-
dogrel.40 Contributory to this is the reduced require-
ment of metabolism of prasugrel and ticagrelor, which
decreases the time of onset of action and also limits the
potential for drug interactions. Ticagrelor itself is a dir-
ectly acting reversible agent,23 whereas prasugrel, a thie-
nopyridine, requires a single rapid hydrolysation step to
active metabolite. Interestingly, higher circulating
esterases are found in patients with diabetes,39 which, in
theory, would ameliorate this activation step, while
inversely it would enhance clopidogrel’s conversion to
inactive metabolite.3
The diabetes patient population requiring insulin
therapy is trending towards increased beneﬁt from the
newer medications. As aforementioned, this represents a
marker of severity and duration of diabetes, and func-
tional studies have shown a muted response to clopido-
grel in patients treated with insulin compared to oral
medication.47 This would suggest that the insulin-
dependent group would have added beneﬁt from a
more potent P2Y12 inhibitor. Further to this, insulin has
been noted in vitro to reduce platelet aggregation by
inhibition of the P2Y12 receptor, which, paradoxically, is
in agreement with the ﬁndings of the review, as patients
requiring insulin therapy are those who are most highly
resistant to insulin.47
Against the results of this clinical outcome analysis
favouring prasugrel are small studies of platelet reactivity
testing. These studies have suggested superiority of tica-
grelor over prasugrel at 5–30 days48–50 even in the
DM-speciﬁc population.51 Thirty patients with diabetes
undergoing PCI following an admission with ACS were
evaluated in a prospective, single-blinded, single-centre
crossover study comparing ticagrelor with prasugrel. All
patients were preloaded with clopidogrel, and platelet
reactivity was tested at days 0, 15 and 30 using VerifyNow
P2Y12 functional assay. On day 15, patients were crossed
over to the alternative comparator. The authors con-
cluded that ticagrelor achieved a signiﬁcantly higher
level of platelet inhibition compared to prasugrel at
30 days. Possible explanations are the pretreatment with
alternative thienopyridine to prasugrel (clopidogrel),
although as the authors point out, this is more consist-
ent with clinical practice, and the lack of washout
period. Notably, prior to the crossover of patient groups
from one comparator to the other, the difference in
level of platelet inhibition was not statistically import-
ant.51 Does this mean reversible versus non-reversible
agents would skew the results? Agreement in the discus-
sion is reached that this is only functional testing, and
may not relate to clinical outcomes, particularly as small
population functional tests do not per se correlate with
large study clinical outcomes.52 It does, however, raise
the question of possible alternative pathways unrelated
to platelet reactivity being involved. Furthermore, theor-
etically, ticagrelors’ functional superiority might be at
the expense of a higher bleeding risk,48 however, no
clinical outcome evidence was found in the analysis to
support this.
The variation between the direct functional and indir-
ect clinical ﬁndings solidiﬁes the need for a direct com-
parison study between ticagrelor and prasugrel, with
robust clinical and safety end points. We therefore await
with great anticipation the results of the ISAR REACT 5
randomised control study,53 which will directly compare
ticagrelor and prasugrel in those presenting with ACS
undergoing an invasive strategy. The DM population is a
clear prespeciﬁed subgroup, although patients with DM
will be likely under-represented in this invasive study.23
Guidance
ESC and AHA both have clear guidance about antiplate-
let management in ACS, with published guidelines for
patients presenting with both non-ST elevation ACS
(NSTE-ACS) and ST segment elevation MI (STEMI), all
supporting the use of P2Y12 blockade in addition to
aspirin (Class IA). There is already a move based on
results of the landmark trials reviewed towards isolated
guidance for patients with diabetes.17 54–57
The 2011 ESC guidelines support the preferential use
of prasugrel in the diabetes patient population if P2Y12
antagonist naive and due to undergo PCI for NSTE-ACS,
assuming patients are not at high risk of life-threatening
bleeding.17 57 No speciﬁc preference is suggested in the
STEMI group, where, generally, prasugrel and ticagrelor
are favoured over clopidogrel.54
There are differing views in the 2014 ACCF/AHA
(American College of Cardiology Foundation)
NSTE-ACS guidelines, which state that with regard to
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antiplatelet therapy, patients with diabetes should be
managed identically to the cohort without diabetes.
They support the use of clopidogrel or ticagrelor (IB)
with preference to ticagrelor, where the patient is under-
going early invasive or ischaemia-guided strategy.
Prasugrel is not recommended for upfront therapy in
any patient with ACS, unless undergoing PCI, and not at
high risk of bleeding.55 In the 2013 ACCF/AHA STEMI
guidelines, all P2Y12 inhibitors are given the same level
of evidence without preference. But a minor comment is
made to consider prasugrel in younger patients with DM
with low bleeding risk, ability to continue dual antiplate-
let therapy, and no planned surgery in the next year.56
In 2014, the UK National Institute for Health and
Care Excellence (NICE) has followed suit with support
for prasugrel in the diabetes patients cohort that present
with ACS (STEMI and NSTE-ACS included), and who
have a planned invasive strategy.58 They determined that
in comparison to clopidogrel, prasugrel is judged to be
the dominant treatment; as it is not only more effective
in reducing subsequent events, it actually costs less than
clopidogrel when given to patients with diabetes with
NSTE-ACS managed within the UK National Health
Service framework.
Our ﬁndings support the advice from NICE, and we
await future guidelines from AHA/ESC with regard to a
more tailored approach to ACS management.
Strengths and limitations
The original studies included in this analysis were large
multicentre randomised controlled trials with careful
prespeciﬁcation of the DM subgroup in the major-
ity.7 22 23 34 All the studies were found to have low risk of
bias using the Cochrane risk of bias tool detailed in
online supplementary appendix 1. However, the analysis
is restricted to published literature, all in peer-reviewed
journals, but an element of publication bias cannot be
excluded. Further papers where we cannot exclude ad
hoc subgroup analysis are at risk of statistical error.8 19 32
The deﬁnition of DM is not clearly explored in every
study population, which may be open to differing inter-
pretation. Four clearly state previous diagnosis of dia-
betes was required; however, this was only inferred in
others. Only PLATO has analysed data on all partici-
pants on the basis of HbA1c which would enable pick up
of patients previously undiagnosed with DM, arguably
those at highest risk.
Indirect comparison analysis does require homogen-
eity of those compared, which is supported by the ﬁnd-
ings of the Cochrane Q statistics observing absence of
heterogeneity in the clopidogrel versus control group.
Random effects relative risk was required for the com-
bination risk of prasugrel compared to clopidogrel in
light of heterogeneity, which needs to be taken into
account when considering the primary outcome indirect
comparison. However, the remaining outcomes indir-
ectly compared are single-study comparisons with similar
design. In the analysis of major bleeding risk, we used
results generated from identical scoring schemes (TIMI)
to maximise homogeneity.
CONCLUSIONS
In patients with diabetes who present with ACS, the add-
ition of a P2Y12 receptor inhibitor is superior to placebo
in reducing CV mortality, non-fatal MI and non-fatal
CVA without signiﬁcantly increasing major bleeding
events. There is a trend to superiority of prasugrel in
this cohort, particularly in those undergoing PCI,
without ampliﬁed risk of major bleeding. There is a
need for the most effective antiplatelet strategy for
patients with diabetes to be further explored with dedi-
cated randomised controlled studies.
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